RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

This study tested a new RSV vaccine given as nose drops to 88 children aged 4 months to 5 years. The vaccine uses a weakened live virus to safely teach the immune system to fight RSV. Researchers monitored side effects and measured antibody levels to see if the vaccine triggers p…

This study looked at whether giving an RSV vaccine and a COVID-19 booster at the same time is safe and works well in adults aged 50 and up. About 841 people took part. The goal was to see if the immune response is similar to getting the vaccines separately.

This study tested an experimental RSV vaccine in 386 adults, including lung and kidney transplant recipients and healthy older adults. The goal was to see if the vaccine triggers a strong immune response and is safe for people with weakened immune systems. Researchers compared on…

This study tested an experimental RSV vaccine in adults aged 18-49 who are at increased risk for RSV disease, comparing their immune response and safety to adults aged 60 and older. Around 1,459 participants took part. The goal was to see if the vaccine works as well in younger h…

This study tested a single shot of an experimental RSV vaccine in 751 older adults (60+) and at-risk adults (50-59) in India. The goal was to see if the vaccine boosts the body's defenses against RSV, a virus that can cause serious lung infections. Researchers measured immune res…

This study tested an experimental RSV vaccine in over 2,600 adults aged 60 and older, including participants in China and overseas. The goal was to see if the vaccine produces a strong immune response and is safe. Researchers also tracked whether vaccinated participants got sick …

This study tested a medicine called nirsevimab in 33 Japanese infants under 1 year old who have health problems like heart or lung disease, weak immune systems, Down syndrome, or were born early. The goal was to see if two doses given 5-6 months apart are safe and help protect ag…

This study tested a single injection of TNM001, a lab-made antibody, to prevent severe RSV lung infections in high-risk infants under 1 year old. About 315 babies received either the antibody or a placebo and were monitored for 270 days. The goal was to see if the shot safely red…

This study tested an injection called TNM001 to see if it can prevent serious lung infections caused by RSV in babies under one year old. Over 2,200 infants received either the shot or a placebo during their first RSV season. The goal was to measure how well the shot works and if…

This follow-up study looked at the safety of a maternal RSV vaccine in women who had received it during earlier clinical trials. About 3,855 participants were monitored during any subsequent pregnancy within two years after vaccination. No new vaccine or treatment was given; the …